Literature DB >> 23806888

Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction.

Hongyan Dai1, Xiaolu Li, Tao He, Yanping Wang, Zhengzhong Wang, Shoudong Wang, Mingqing Xing, Wenjuan Sun, Huamin Ding.   

Abstract

Nesfatin-1 is a novel anorexigenic hormone which has close relationship with diabetes, obese, anorexia nervosa, psychiatric disorders and neurogenic diseases. The aim of our study was to evaluate levels of plasma nesfatin-1 among patients presenting with coronary artery disease and the correlation between nesfatin-1 levels and other clinical parameters. Fasting plasma levels of nesfatin-1 were tested in 48 acute myocardial infarction (AMI) patients, 74 stable angina pectoris (SAP) patients and 34 control subjects. All of them were examined by coronary angiography. The severity of coronary atherosclerosis was assessed using the Gensini score. Plasma nesfatin-1 levels were significantly lower in AMI group than SAP group or control group (0.91±0.08 ng/mL vs. 0.98±0.19 ng/mL and 1.09±0.39 ng/mL, respectively, P<0.05). In AMI patients, plasma nesfatin-1 levels were negatively correlated with high-sensitivity C-reactive protein, neutrophil% or Gensini scores. Such information implies that lower nesfatin-1 concentration may play a very important role in the development of AMI.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Angina pectoris; Angiography; Nesfatin-1

Mesh:

Substances:

Year:  2013        PMID: 23806888     DOI: 10.1016/j.peptides.2013.06.006

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  15 in total

1.  A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma.

Authors:  Huan Xu; Wenzhi Li; Kai Qi; Juan Zhou; Meng Gu; Zhong Wang
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

2.  Necroptosis and RhoA/ROCK pathways: molecular targets of Nesfatin-1 in cardioprotection against myocardial ischemia/reperfusion injury in a rat model.

Authors:  Masoomeh Sharifi; Donya Nazarinia; Fatemeh Ramezani; Yaser Azizi; Nasim Naderi; Nahid Aboutaleb
Journal:  Mol Biol Rep       Date:  2021-03-23       Impact factor: 2.316

3.  Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Serkan Sivri; Erdoğan Sökmen; Mustafa Çelik; Kenan Güçlü
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

4.  NEW BIOMARKERS TO PREDICT CARDIOVASCULAR RISK IN PATIENTS WITH ADRENAL INCIDENTALOMA; IRISIN AND NESFATIN-1.

Authors:  M Can; M Kocabaş; M Karaköse; Y Alsancak; F H Yerlikaya; H Caliskan Burgucu; I Cordan; C Kadiyoran; M Kulaksızoğlu; F Karakurt
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

Review 5.  NUCB2: roles in physiology and pathology.

Authors:  Qing Zhou; Ying Liu; Ranran Feng; Wenling Zhang
Journal:  J Physiol Biochem       Date:  2022-06-09       Impact factor: 5.080

6.  Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.

Authors:  Peng Shen; Yingying Han; Bo Cai; Yu Wang
Journal:  Sleep Breath       Date:  2014-07-24       Impact factor: 2.816

Review 7.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

8.  The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Mevlüt Serdar Kuyumcu; Aliye Kuyumcu; Çağrı Yayla; Mustafa Bilal Özbay; Sefa Ünal; Burak Açar; Cemil Nural; Almila Şenat; Gülhan Samur
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

9.  Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.

Authors:  Shimei Ding; Wei Qu; Shuangsuo Dang; Xuan Xie; Jing Xu; Yuhuan Wang; Aiyu Jing; Chunhong Zhang; Junhong Wang
Journal:  Med Sci Monit       Date:  2015-04-04

10.  Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.

Authors:  Guang-Ming Liu; Zi-Qiang Xu; Hong-Shun Ma
Journal:  Dis Markers       Date:  2018-09-19       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.